• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Johns Hopkins Rheumatology

Show Search
Hide Search
  • About Us
    • Our History
    • Our Faculty
    • Rheumatology Fellowship
    • Administrative Core
    • Contact Us
    • eNews Signup
  • Make an Appointment
    • Clinic Information
    • Specialty Clinics
  • Our Research
    • Current Research Studies
    • Andrade Lab
    • Darrah Lab
    • Konig Lab
    • Rosen Casciola Lab
    • RDRCC
    • Bayview Immunomics Core (BIC)
  • Charitable Giving
    • Dr. John Welton Fellowship in Rheumatology
    • Dr. Ira T. Fine Discovery Fund
    • Dr. Nadia D. Morgan Memorial Fund
  • News
    • LEAP Magazine
  • Education
    • Advances in the Diagnosis and Treatment of the Rheumatic Diseases Course
    • RheumTV – Patient Education Video Library
Home / News / Research / Does timing of routine blood work matter for patients on methotrexate?

Does timing of routine blood work matter for patients on methotrexate?

August 29, 2016 By Erika Darrah

Summary

A new study by Clifton O. Bingham III, M.D., Christopher A. Mecoli, M.D., and Nikolay G. Delev M.D. from the Division of Rheumatology evaluated changes in blood levels of liver enzymes, markers of liver damage, over one week after methotrexate was given to patients with rheumatoid arthritis (RA).  Sequential blood samples from RA patients on stable doses of methotrexate were taken over the course of 1 week and no significant changes in liver enzyme levels were observed. However, the addition of other medications, such as ibuprofen, in the setting of methotrexate can increase enzyme levels.

Why was this study done?

In clinical practice, it is common to observe abnormal increases in the level of liver enzymes, called transaminases, during blood work for monitoring toxicity of certain drugs. The drug methotrexate is taken once a week and is used to treat a variety of diseases, including RA. However, its long-term use has been linked to liver abnormalities in some patients.  Many doctors have suggested that such lab abnormalities can sometimes be attributed to sampling blood for toxicity monitoring too close to methotrexate dosing (i.e. having labs performed the day after a patient takes methotrexate). The aim of our study was to evaluate changes in transaminase levels over one week after methotrexate administration in patients with rheumatoid arthritis (RA).

How was this study done?

We evaluated 13 patients with RA taking stable doses of methotrexate and folic acid. Patients received their usual dose of methotrexate administered at a specified time, and then sequential blood samples were drawn over the course of 7 days. Transaminase levels in the blood were measured at each time point.

What were the major findings?

We did not observe any significant change in the levels of transaminases in the blood over 1 week in relationship to when methotrexate was administered. However, the addition of other medications, such as ibuprofen or naproxen, to a stable methotrexate regimen may result in transaminase abnormalities.

What is the impact of this work?

When transaminase abnormalities are seen in someone taking methotrexate, it is common that physicians will attribute this change to the methotrexate and change the dose. Our study suggests that other newly introduced drugs may cause the abnormality and that this possibility should be ruled out, followed by a repeat blood test before the dose of methotrexate is changed.

This research was supported by:

The Johns Hopkins Rheumatic Disease Research Core Center (RDRCC, P30-AR053503) and the T32 training grant (AR48522).

Link to original research article:

Measuring transaminases in patients with rheumatoid arthritis on weekly methotrexate: does timing of blood testing matter?. Mecoli CA, Delev NG, Bingham CO 3rd. Clin Rheumatol. 2016 Jul 29.

Receive the Latest News from Johns Hopkins Rheumatology

Receive the Latest News from Johns Hopkins Rheumatology

Join our mailing list to receive the latest news and updates from Johns Hopkins Rheumatology.

Interested In

You have Successfully Subscribed!

Filed Under: Research Tagged With: Featured 2

Erika Darrah

Erika Darrah, Ph.D. is an Assistant Professor of Medicine in the Johns Hopkins University Division of Rheumatology with an interest understanding the mechanisms that drive the development of rheumatic diseases.

Use of this Site

All information contained within the Johns Hopkins Division of Rheumatology website is intended for educational purposes only. Physicians and other health care professionals are encouraged to consult other sources and confirm the information contained within this site. Consumers should never disregard medical advice or delay in seeking it because of something they may have read on this website.

Primary Sidebar

Rheumatology News

  • News
  • Promotions

Recent News

LEAP – Winter 2023: Big Data, Individualized Care

February 23, 2023

LEAP Rounds – Holiday 2022

November 9, 2022

Dr. Rachel Wallwork named ACR Distinguished Fellow

October 19, 2022

RheumTV Logo

Rheum.TV is an educational platform created to help patients living with a rheumatic disease. With over 100 disease education videos produced by the team at Johns Hopkins Rheumatology.

Visit RheumTV

Footer

Rheumatology Specialty Care Centers

  • Johns Hopkins Arthritis Center
  • Johns Hopkins Lupus Center
  • Johns Hopkins Lyme Disease Research Center
  • Johns Hopkins Myositis Center
  • Johns Hopkins Scleroderma Center
  • Johns Hopkins Sjögren’s Syndrome Center
  • Johns Hopkins Vasculitis Center

Connect with Us

  • Facebook
  • Twitter
  • YouTube
U.S. News and World Report Rankings Badge

Johns Hopkins Medicine

© 2023 Johns Hopkins Rheumatology - Patient Privacy